Glaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook
+2 new sources since this summary was written
Glaukos Corp. posted third‑quarter 2026 net sales of $211 million, up 58% year‑over‑year, and posted adjusted earnings of $0.47 per share, beating consensus forecasts. The company raised its full‑year 2026 net‑sales guidance to $775‑$785 million and offered a preliminary 2027 revenue target of $1 billion, citing strong performance of its iDose TR glaucoma implant and the newly launched Epioxa corneal therapy. Management highlighted an 88% non‑GAAP gross‑margin, $28.5 million of non‑GAAP net income and $59 million of corneal‑health sales, including $53 million of Epioxa net sales.
Why it matters
The raised 2026 guidance and preliminary 2027 target increase the company’s projected revenue base, which analysts note could lift the stock’s valuation multiples (the company’s price targets were raised by BTIG to $205 and by Mizuho to $190). The earnings beat and higher guidance also triggered a post‑earnings rally of roughly 30% in GKOS shares.
Key facts
- 1Q3 2026 net sales were $211 million, up 58% YoY. tradingview.com
- 2Adjusted EPS for Q3 2026 was $0.47 per share. finance.yahoo.com
- 3Full‑year 2026 net‑sales guidance was raised to $775 million‑$785 million. finance.yahoo.com
- 4Preliminary 2027 revenue guidance was set at $1 billion. finance.yahoo.com
- 5Non‑GAAP gross margin expanded to approximately 88%. finance.yahoo.com
- 6Corneal‑health franchise generated $59 million in Q3 sales, with Epioxa contributing about $53 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 19 of 19 sources. Not investment advice. Figures are as stated by the linked sources.